Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring STEMI, infarct size, primary PCI, no-reflow, ST-elevation myocardial infarction
Eligibility Criteria
Inclusion Criteria: Clinical symptoms: Angina < 12 h persistent Angina > 30 min. ECG-Criteria: ST-elevation > 1mm in ≥ 2 extremity leads ST-elevation > 2mm in ≥ 2 contiguous anterior leads Informed consent Exclusion Criteria: No consent Pregnancy Allergy against abciximab, ASA or heparin Active peptic ulcus ventriculi or duodeni Active non-superficial bleeding Major surgical intervention, intracerebral interventions, puncture central artery < 4 weeks Active internal bleeding Cerebrovascular complications < 2 years Known coagulation disorders, thrombocytopenia Arteriovenous malformations or aneurysms Severe Liver or renal dysfunction Severe untreated hypertension Active vasculitis Previous thrombolysis < 12 h
Sites / Locations
- University of Leipzig - Heart Center